The Moderate Dry Eye market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Moderate Dry Eye pipeline products will significantly revolutionize the Moderate Dry Eye market dynamics.

DelveInsight’s “Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Moderate Dry Eye, historical and forecasted epidemiology as well as the Moderate Dry Eye market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Moderate Dry Eye market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Moderate Dry Eye market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Moderate Dry Eye Market Forecast

Some of the key facts of the Moderate Dry Eye Market Report:

• The Moderate Dry Eye market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In April 2025, The U.S. Food and Drug Administration (FDA) declined to approve Aldeyra Therapeutics’ Dry Eye treatment, reproxalap, citing insufficient efficacy data. This marks the second rejection, following a similar outcome in 2023. The FDA recommends at least one additional trial to demonstrate the drug’s effectiveness.

• In February 2025, Cambium Bio revealed that the FDA has approved the protocol for its Phase III clinical trials of Elate Ocular, aimed at treating moderate to severe Dry Eye.

• In January 2025, Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company focused on developing innovative treatments for ophthalmic conditions, has announced the completion of the final patient visit in its Phase III clinical trial of ST-100 (vezocolmitide), its lead therapeutic candidate for Dry Eye

• The anticipated launch of new therapies, including RGN-259, Tavilermide (MIM-D3), and AR-15512, is expected to drive changes in the total market size of DED in the coming years.

• According to DelveInsight’s assessment, the estimated total number of diagnosed prevalent cases of DED in the 7MM was approximately 54.7 million in 2023.

• In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of DED among European countries, with around 6.1 million cases, followed by Germany with approximately 5 million. Spain, meanwhile, had the lowest prevalence, with 2.1 million cases.

• The US accounted for the highest percentage of diagnosed prevalent cases of DED among the 7MM countries, representing 41%, while Japan had the lowest, at 19%. This trend is expected to continue throughout the forecast period.

• In the US, gender-specific data showed around 9.4 million diagnosed prevalent cases of DED among males and approximately 13 million among females. Projections suggest that by 2032, the prevalence among females will continue to outpace that of males.

• In 2023, severity-specific data indicated that mild DED affected the largest group in the US, with around 11.2 million cases, while severe cases numbered 4.5 million. This trend, with mild cases outnumbering severe ones, is expected to persist throughout the forecast period.

• Key Moderate Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

• Key Moderate Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

• The Moderate Dry Eye epidemiology based on gender analyzed that females are more affected by Moderate Dry Eye than males

Moderate Dry Eye Overview

Moderate dry eye is a more advanced stage of dry eye disease characterized by persistent discomfort, increased tear film instability, and mild inflammation of the ocular surface. Symptoms include a burning or stinging sensation, eye fatigue, sensitivity to light, blurry vision, and a feeling of something in the eye. Unlike mild cases, moderate dry eye may require more than just over-the-counter drops—such as prescription eye drops, anti-inflammatory treatments, punctal plugs, or lifestyle modifications—to manage symptoms and prevent further progression or damage to the eye surface. Regular monitoring by an eye care professional is often recommended.

Get a Free sample for the Moderate Dry Eye Market Report –

https://www.delveinsight.com/report-store/moderate-dry-eye-market

Moderate Dry Eye Market

The dynamics of the Moderate Dry Eye market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“Of the emerging therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies),and many other compelling treatments are expected to change the market scenario of Moderate Dry Eye in the upcoming years.”

Moderate Dry Eye Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Moderate Dry Eye Epidemiology Segmentation:

The Moderate Dry Eye market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Moderate Dry Eye

• Prevalent Cases of Moderate Dry Eye by severity

• Gender-specific Prevalence of Moderate Dry Eye

• Diagnosed Cases of Episodic and Chronic Moderate Dry Eye

Download the report to understand which factors are driving Moderate Dry Eye epidemiology trends @ Moderate Dry Eye Epidemiological Insights

Moderate Dry Eye Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Moderate Dry Eye market or expected to get launched during the study period. The analysis covers Moderate Dry Eye market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Moderate Dry Eye Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Moderate Dry Eye treatment, visit @ Moderate Dry Eye Medications

Moderate Dry Eye Therapies and Key Companies

• PL9643: Palatin Technologies

• NOV03: Novaliq

• CyclASol: Novaliq

• MC2-03: mc2 therapeutics

Scope of the Moderate Dry Eye Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Moderate Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

• Key Moderate Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

• Moderate Dry Eye Therapeutic Assessment: Moderate Dry Eye current marketed and Moderate Dry Eye emerging therapies

• Moderate Dry Eye Market Dynamics: Moderate Dry Eye market drivers and Moderate Dry Eye market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Moderate Dry Eye Unmet Needs, KOL’s views, Analyst’s views, Moderate Dry Eye Market Access and Reimbursement

Discover more about therapies set to grab major Moderate Dry Eye market share @ Moderate Dry Eye Treatment Landscape

Table of Contents

1. Moderate Dry Eye Market Report Introduction

2. Executive Summary for Moderate Dry Eye

3. SWOT analysis of Moderate Dry Eye

4. Moderate Dry Eye Patient Share (%) Overview at a Glance

5. Moderate Dry Eye Market Overview at a Glance

6. Moderate Dry Eye Disease Background and Overview

7. Moderate Dry Eye Epidemiology and Patient Population

8. Country-Specific Patient Population of Moderate Dry Eye

9. Moderate Dry Eye Current Treatment and Medical Practices

10. Moderate Dry Eye Unmet Needs

11. Moderate Dry Eye Emerging Therapies

12. Moderate Dry Eye Market Outlook

13. Country-Wise Moderate Dry Eye Market Analysis (2019–2032)

14. Moderate Dry Eye Market Access and Reimbursement of Therapies

15. Moderate Dry Eye Market Drivers

16. Moderate Dry Eye Market Barriers

17. Moderate Dry Eye Appendix

18. Moderate Dry Eye Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/